Literature DB >> 29780711

The continued EGFR-TKI with cytotoxic chemotherapy at progression-poison or medicine?

Shin-Kyo Yoon1, Chang Min Choi1,2, Jae Cheol Lee1.   

Abstract

Entities:  

Year:  2018        PMID： 29780711      PMCID： PMC5943226          DOI： 10.21037/tlcr.2018.03.23

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  15 in total

1.  Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.

Authors:  Jean-Charles Soria; Yi-Long Wu; Kazuhiko Nakagawa; Sang-We Kim; Jin-Ji Yang; Myung-Ju Ahn; Jie Wang; James Chih-Hsin Yang; You Lu; Shinji Atagi; Santiago Ponce; Dae Ho Lee; Yunpeng Liu; Kiyotaka Yoh; Jian-Ying Zhou; Xiaojin Shi; Alan Webster; Haiyi Jiang; Tony S K Mok
Journal:  Lancet Oncol       Date:  2015-07-06       Impact factor: 41.316

2.  Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations.

Authors:  Kenichi Nishie; Tomoya Kawaguchi; Akihiro Tamiya; Tomoyasu Mimori; Naoko Takeuchi; Yoshinobu Matsuda; Naoki Omachi; Kazuhiro Asami; Kyoichi Okishio; Shinji Atagi; Tomohisa Okuma; Akihito Kubo; Yoshihito Maruyama; Shinzoh Kudoh; Minoru Takada
Journal:  J Thorac Oncol       Date:  2012-11       Impact factor: 15.609

3.  First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.

Authors:  Keunchil Park; Chong-Jen Yu; Sang-We Kim; Meng-Chih Lin; Virote Sriuranpong; Chun-Ming Tsai; Jong-Seok Lee; Jin-Hyoung Kang; K C Allen Chan; Pablo Perez-Moreno; Peter Button; Myung-Ju Ahn; Tony Mok
Journal:  JAMA Oncol       Date:  2016-03       Impact factor: 31.777

4.  A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.

Authors:  Fred R Hirsch; Fairooz Kabbinavar; Tim Eisen; Renato Martins; Fredrick M Schnell; Rafal Dziadziuszko; Katherine Richardson; Frank Richardson; Bret Wacker; David W Sternberg; Jason Rusk; Wilbur A Franklin; Marileila Varella-Garcia; Paul A Bunn; Ross Camidge; D Ross Camidge
Journal:  J Clin Oncol       Date:  2011-08-08       Impact factor: 44.544

5.  Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.

Authors:  Jae Cheol Lee; Seung Hun Jang; Kye Young Lee; Young-Chul Kim
Journal:  Cancer Res Treat       Date:  2013-06-30       Impact factor: 4.679

6.  Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.

Authors:  Ying Cheng; Haruyasu Murakami; Pan-Chyr Yang; Jianxing He; Kazuhiko Nakagawa; Jin Hyoung Kang; Joo-Hang Kim; Xin Wang; Sotaro Enatsu; Tarun Puri; Mauro Orlando; James Chih-Hsin Yang
Journal:  J Clin Oncol       Date:  2016-08-09       Impact factor: 44.544

7.  Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

Authors:  Yi-Long Wu; Jin Soo Lee; Sumitra Thongprasert; Chong-Jen Yu; Li Zhang; Guia Ladrera; Vichien Srimuninnimit; Virote Sriuranpong; Jennifer Sandoval-Tan; Yunzhong Zhu; Meilin Liao; Caicun Zhou; Hongming Pan; Victor Lee; Yuh-Min Chen; Yan Sun; Benjamin Margono; Fatima Fuerte; Gee-Chen Chang; Kasan Seetalarom; Jie Wang; Ashley Cheng; Elisna Syahruddin; Xiaoping Qian; James Ho; Johan Kurnianda; Hsingjin Eugene Liu; Kate Jin; Matt Truman; Ilze Bara; Tony Mok
Journal:  Lancet Oncol       Date:  2013-06-17       Impact factor: 41.316

Review 8.  Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma.

Authors:  Yoon Soo Chang; Chang-Min Choi; Jae Cheol Lee
Journal:  Tuberc Respir Dis (Seoul)       Date:  2016-10-05

9.  Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.

Authors:  Minghui Zhang; Hongsheng Guo; Shu Zhao; Yan Wang; Maopeng Yang; Jiawei Yu; Yubo Yan; Yan Wang
Journal:  Oncotarget       Date:  2016-06-28

10.  Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.

Authors:  Puyu Shi; You-Take Oh; Liang Deng; Guojing Zhang; Guoqing Qian; Shuo Zhang; Hui Ren; Grant Wu; Benjamin Legendre; Emily Anderson; Suresh S Ramalingam; Taofeek K Owonikoko; Mingwei Chen; Shi-Yong Sun
Journal:  Clin Cancer Res       Date:  2017-08-01       Impact factor: 12.531
View more
  1 in total

1.  Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study.

Authors:  Ziqing Zeng; Bo Yan; Yulong Chen; Lianmin Zhang; Jianquan Zhu; Fan Yang; Feng Wei; Terence Chi Chun Tam; Diego Kauffmann-Guerrero; Ross Andrew Soo; Xiubao Ren; Jian You
Journal:  Transl Lung Cancer Res       Date:  2020-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.